Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0382 in Non-diabetic Obese Subjects
NCT03625778Phase 1Completed
- Sponsor
- MedImmune
- Start
- Aug 2018
- Primary completion
- Aug 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cotadutide in obesity (6 cohorts), sponsored by MedImmune. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs and 6 more. Started Aug 2018; status: completed.
02
Drugs
cotadutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03625778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625778.